Copyright
©2007 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Feb 7, 2007; 13(5): 732-739
Published online Feb 7, 2007. doi: 10.3748/wjg.v13.i5.732
Published online Feb 7, 2007. doi: 10.3748/wjg.v13.i5.732
A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation
San-Ren Lin, The 3rd Hospital, Beijing Medical University, Beijing, China
Mei-Yun Ke, Peking Union Medical College Hospital, Beijing, China
Jin-Yan Luo, The 2nd Hospital of Xian Jiaotong University, Shanxi, China
Yao-Zong Yuan, Shanghai Ruijin Hospital, Shanghai, China
Ji-Yao Wang, Shanghai Zhongshan Hospital, Shanghai, China
Shelley diTommaso, Verena Walter, Novartis Pharma AG, Basel, Switzerland
Jiaqing Huang, Novartis Pharmaceuticals Corp, East Hanover, New Jersey, United States
Author contributions: All authors contributed equally to the work.
Correspondence to: Jiaqing Huang, MD, PhD, Novartis Pharmaceuticals Corporation, Gastroenterology/Urology Therapeutic Area, Clinical Development and Medical Affairs, One Health Plaza, Building 405/2019, East Hanover, NJ 07936, United States. jiaqing.huang@novartis.com
Telephone: +1-862-7787103 Fax: +1-973-7812390
Received: October 19, 2006
Revised: December 3, 2006
Accepted: December 21, 2006
Published online: February 7, 2007
Revised: December 3, 2006
Accepted: December 21, 2006
Published online: February 7, 2007
Core Tip